Status: Recruiting
Zopa Retreatment and Vector Shedding in Adults With RRP
This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.
Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Precigen, IncUpdated: Dec 15, 2025Locations: 3
Eligibility criteria
Age 18 years and older. [+7]
Conditions or therapies that increase risk or interfere with participation per i... [+6]